Christopher R. Bolen, Siyuan Ding, Michael D. Robek, Steven H. Kleinstein – 8 August 2013 – Despite activating similar signaling cascades, the type I and type III interferons (IFNs) differ in their ability to antagonize virus replication. However, it is not clear whether these cytokines induce unique antiviral states, particularly in the liver, where the clinically important hepatitis B and C viruses cause persistent infection.

Andreas L. Birkenfeld, Gerald I. Shulman – 8 August 2013 – Nonalcoholic fatty liver disease (NAFLD), hepatic insulin resistance, and type 2 diabetes are all strongly associated and are all reaching epidemic proportions. Whether there is a causal link between NAFLD and hepatic insulin resistance is controversial.

Frédéric P. Lemaigre – 8 August 2013

Andreas L. Birkenfeld, Gerald I. Shulman – 8 August 2013 – Nonalcoholic fatty liver disease (NAFLD), hepatic insulin resistance, and type 2 diabetes are all strongly associated and are all reaching epidemic proportions. Whether there is a causal link between NAFLD and hepatic insulin resistance is controversial.

Rohit A. Sinha, Benjamin L. Farah, Brijesh K. Singh, Monowarul M. Siddique, Ying Li, Yajun Wu, Olga R. Ilkayeva, Jessica Gooding, Jianhong Ching, Jin Zhou, Laura Martinez, Sherwin Xie, Boon‐Huat Bay, Scott A. Summers, Christopher B. Newgard, Paul M. Yen – 8 August 2013 – Caffeine is one of the world's most consumed drugs. Recently, several studies showed that its consumption is associated with lower risk for nonalcoholic fatty liver disease (NAFLD), an obesity‐related condition that recently has become the major cause of liver disease worldwide.

Jamuna Karkhanis, Elizabeth C. Verna, Matthew S. Chang, R. Todd Stravitz, Michael Schilsky, William M. Lee, Robert S. Brown, for the Acute Liver Failure Study Group – 8 August 2013 – Drug‐induced and indeterminate acute liver failure (ALF) might be due to an autoimmune‐like hepatitis that is responsive to corticosteroid therapy. The aim of this study was to evaluate whether corticosteroids improve survival in fulminant autoimmune hepatitis, drug‐induced, or indeterminate ALF, and whether this benefit varies according to the severity of illness.

Manfred Wiese, Janett Fischer, Micha Löbermann, Uwe Göbel, Kurt Grüngreiff, Wolfgang Güthoff, Ulrike Kullig, Franziska Richter, Ingolf Schiefke, Hannelore Tenckhoff, Alexander Zipprich, Thomas Berg, Tobias Müller, for the East German HCV Study Group – 8 August 2013 – The natural course of HCV infection remains controversial. The German HCV (1b)‐contaminated anti‐D cohort provides an ideal population to investigate the natural course of HCV infection in a large, homogenous cohort of young women from the date of HCV inoculation.

David N. Assis, Lin Leng, Xin Du, Clarence K. Zhang, Gerrit Grieb, Melanie Merk, Alvaro Baeza Garcia, Catherine McCrann, Julius Chapiro, Andreas Meinhardt, Yuka Mizue, David J. Nikolic‐Paterson, Jürgen Bernhagen, Marshall M. Kaplan, Hongyu Zhao, James L. Boyer, Richard Bucala – 2 August 2013 – The role of the cytokine, macrophage migration inhibitory factor (MIF), and its receptor, CD74, was assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC).

Michael W. Fried, Maria Buti, Gregory J. Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele Smedt, Maria Beumont‐Mauviel – 2 August 2013 – The phase IIb, double‐blind, placebo‐controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once‐daily (QD) with pegylated interferon (Peg‐IFN)‐α‐2a and ribavirin (RBV) in treatment‐naïve patients with HCV genotype 1 infection.

Michael W. Fried, Maria Buti, Gregory J. Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele Smedt, Maria Beumont‐Mauviel – 2 August 2013 – The phase IIb, double‐blind, placebo‐controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once‐daily (QD) with pegylated interferon (Peg‐IFN)‐α‐2a and ribavirin (RBV) in treatment‐naïve patients with HCV genotype 1 infection.